In regulatory pathways, what does "NDA" stand for?

The term "NDA" stands for New Drug Application. This is a regulatory submission made to the U.S. Food and Drug Administration (FDA) for the approval of a new pharmaceutical product. The NDA process includes data on the drug's effectiveness, safety, labeling, and manufacturing processes. It is a critical step in bringing a new drug to market, as it provides the FDA with the necessary information to evaluate whether the product should be approved for commercial use.

Understanding NDA is essential in the context of regulatory pathways because it illustrates the mechanisms through which new drugs are assessed and approved, impacting public health and safety. The other options do not relate to established terminology recognized in regulatory affairs, making it clear that only "New Drug Application" accurately reflects the standard used in the context of drug regulation.